A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients

A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients

Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.

Inclusion Criteria:

• Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria
• Meet DSM-IV criteria for Dementia of the Alzheimer type
• MMSE score : 16 to 26 etc.

Exclusion Criteria:

• Meet the exclusion criteria of MRI at screening.
• A history of significant neurodegenerative diseases or dementia other than Alzheimer's disease.

etc.